Blurbs

Jazz Pharmaceuticals (JAZZ) Gets a Buy Rating from J.P. Morgan

J.P. Morgan analyst Jessica Fye maintained a Buy rating on Jazz Pharmaceuticals (JAZZResearch Report) yesterday and set a price target of $183.00. The company’s shares closed last Thursday at $151.17.

According to TipRanks.com, Fye is a 4-star analyst with an average return of 9.6% and a 56.1% success rate. Fye covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Crinetics Pharmaceuticals, and Intra-Cellular Therapies.

Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $198.60, implying a 28.5% upside from current levels. In a report released yesterday, BMO Capital also maintained a Buy rating on the stock with a $188.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $169.98 and a one-year low of $117.64. Currently, Jazz Pharmaceuticals has an average volume of 523.5K.

Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Read More on JAZZ:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos